Cardiovascular Safety Assessment in Early-Phase Clinical Studies: A Meta-Analytical Comparison of Exposure-Response Models.

CPT Pharmacometrics Syst Pharmacol

Biotherapeutics Clinical Pharmacology, Pfizer Global Research and Development, Cambridge, Massachusetts, USA.

Published: June 2016

Exposure-response analysis of QT interval in clinical studies has been proposed as a thorough QT study alternative. Many exposure-response model structures have been proposed for cardiovascular (CV) safety markers, but few studies have compared models across multiple drugs. To recommend preferred drug-effect exposure-response models on vital signs and electrocardiogram (ECG) intervals, an individual-level model-based meta-analysis (39 studies and 1,291 subjects) compared 90 model structures. Models were selected to describe the data and cross-validate studies on the same drug. The most commonly selected baseline model was an unstructured model (estimation of a value at each study nominal time) for all measures but blood pressure. The unstructured model estimated a better cross-validated drug-effect when considering all markers. A linear model was the most commonly selected to characterize drug-effect on all markers. We propose these models as a starting point assisting with CV safety exposure-response assessment in nondedicated small studies with healthy subjects.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5131889PMC
http://dx.doi.org/10.1002/psp4.12086DOI Listing

Publication Analysis

Top Keywords

cardiovascular safety
8
clinical studies
8
exposure-response models
8
model structures
8
commonly selected
8
unstructured model
8
studies
6
model
6
exposure-response
5
models
5

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!